Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.

Goel, Arun Kumar; Zamre, Vaishali; Hari, Shreebha

Goel, Arun Kumar; Zamre, Vaishali; Hari, Shreebha.

Affiliation

Goel AK; Department of Surgical Oncology, Max Superspecialty Hospital, W-3, Sector 1, Vaishali, Ghaziabad, UP, 201012, India. arun.goel07@gmail.com.
Zamre V; Department of Surgical Oncology, Max Superspecialty Hospital, W-3, Sector 1, Vaishali, Ghaziabad, UP, 201012, India.
Hari S; Department of Radiation Oncology, Max Superspecialty Hospital, Vaishali, Ghaziabad, India.

Breast Cancer Res Treat ; 183(2): 489-490, 2020 Sep.

Article de En | MEDLINE | ID: mdl-32647941

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Récepteur ErbB-2 / Lapatinib Limites: Female / Humans Langue: En Journal: Breast Cancer Res Treat Année: 2020 Type de document: Article Pays d'affiliation: Inde Pays de publication: Pays-Bas

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google